Supplementary Figure S2 from Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab

• DOI: 10.1158/1078-0432.22474827
• Publication Date: 2023-04-01T20:37:01Z
• Authors: Brandon W. Higgs; Christopher A. Mo...; Katie Streicher; Philip Z. Brohawn; Fernanda Pilataxi; Ashok Gupta; Koustubh Ranade
• Keywords: Durvalumab

<p>Supplemental Figure S2. Association of IFNγ+ signature with ORR at higher cutoffs in NSCLC and UC patients.</p>